The current recommendations for the diagnostics and therapy in mineral and bone disorders (MBD) in chronic kidney disease (CKD) developed by an international group of experts KDIGO and the Board of the Polish Nephrology Consultant's Working Group are presented in the paper. MBD--begin already in the early stages of CKD, and are an important cause of increased morbidity and mortality in this population. The main goals of the therapy are to maintain calcium and phosphate homeostasis and to keep serum parathyroid hormone concentrations in the optimal range.